- Home
- WEYS vs IMMP Comparison
WEYS vs IMMP Comparison
Compare WEYS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEYS
- IMMP
- Stock Information
- Founded
- WEYS 1906
- IMMP 1987
- Country
- WEYS United States
- IMMP Australia
- Employees
- WEYS N/A
- IMMP N/A
- Industry
- WEYS Apparel
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- WEYS Consumer Staples
- IMMP Health Care
- Exchange
- WEYS Nasdaq
- IMMP Nasdaq
- Market Cap
- WEYS 294.5M
- IMMP 251.8M
- IPO Year
- WEYS N/A
- IMMP N/A
- Fundamental
- Price
- WEYS $30.48
- IMMP $1.68
- Analyst Decision
- WEYS
- IMMP Buy
- Analyst Count
- WEYS 0
- IMMP 1
- Target Price
- WEYS N/A
- IMMP $7.00
- AVG Volume (30 Days)
- WEYS 10.5K
- IMMP 88.5K
- Earning Date
- WEYS 11-04-2025
- IMMP 10-21-2025
- Dividend Yield
- WEYS 3.58%
- IMMP N/A
- EPS Growth
- WEYS N/A
- IMMP N/A
- EPS
- WEYS 2.69
- IMMP N/A
- Revenue
- WEYS $281,051,000.00
- IMMP $3,306,742.00
- Revenue This Year
- WEYS N/A
- IMMP N/A
- Revenue Next Year
- WEYS N/A
- IMMP $725.37
- P/E Ratio
- WEYS $11.19
- IMMP N/A
- Revenue Growth
- WEYS N/A
- IMMP 31.28
- 52 Week Low
- WEYS $25.51
- IMMP $1.32
- 52 Week High
- WEYS $41.05
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- WEYS 51.56
- IMMP 50.03
- Support Level
- WEYS $29.17
- IMMP $1.60
- Resistance Level
- WEYS $30.76
- IMMP $1.76
- Average True Range (ATR)
- WEYS 0.89
- IMMP 0.06
- MACD
- WEYS 0.01
- IMMP 0.01
- Stochastic Oscillator
- WEYS 56.22
- IMMP 52.94
About WEYS Weyco Group Inc.
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.